IVIG Therapy for Immuno Disorders: 47.5% of denials overturned
In 158 California IMR decisions from 2004 to 2025, reviewers overturned 75 (47.5%). In the last five years: 62.3% of 69. 126 were medical-necessity disputes, 32 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 11 | 63.6% |
| 2022 | 16 | 68.8% |
| 2023 | 9 | 44.4% |
| 2024 | 19 | 42.1% |
| 2025 | 14 | 92.9% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 64 | 50.0% | 47.5% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 35 | 0.0% | 47.5% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 18 | 44.4% | 47.5% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 16 | 62.5% | 47.5% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 15 | 26.7% | 47.5% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 6 | 0.0% | 47.5% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 4 | 25.0% | 47.5% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for immune globulin (Cuvitru). The decision to initiate or continue immunoglobulin replacement therapy should be made based on clinical and laboratory findings supportive of a diagnosis of a clinically significant antibody production defect. This patient’s clinical history (recurrent upper respiratory infections) and recent laboratory evaluation (incomplete response to …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Octagam intravenous immunoglobulin (IVIG) treatment. In this case, the patient has been diagnosed with autoimmune encephalitis (AE). A review of the record establishes that the patient has attempted treatment with high-dose corticosteroids among other treatments. Overall, IVIG therapy is considered to be …”
“The physician reviewer found that a patient has requested authorization and coverage for intravenous immunoglobulin (IVIG) home infusion Octagam 120 gm divided over two to four days, every four weeks, with skilled nursing visits and per diem.The records document that this patient has clinical and electrodiagnostic studies consistent with axonal neuropathy. The report documented reduced velocities but no mention of …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for intravenous immune globulin (IVIG) services provided and five additional IVIG infusion sessions.On review of the available records, this patient does not have a condition that could benefit from treatment with IVIG. Specifically, the records lack documentation of primary humoral immunodeficiency or a need for …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were IVIG Therapy denials for Immuno Disorders overturned?
In 158 California IMR decisions from 2004 to 2025, reviewers overturned 75 (47.5%). In the last five years: 62.3% of 69. 126 were medical-necessity disputes, 32 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.